290 related articles for article (PubMed ID: 34038996)
1. Can reactogenicity predict immunogenicity after COVID-19 vaccination?
Hwang YH; Song KH; Choi Y; Go S; Choi SJ; Jung J; Kang CK; Choe PG; Kim NJ; Park WB; Oh MD
Korean J Intern Med; 2021 Nov; 36(6):1486-1491. PubMed ID: 34038996
[TBL] [Abstract][Full Text] [Related]
2. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Immunogenicity and Reactogenicity of Five Primary Series of COVID-19 Vaccine Regimens against Circulating SARS-CoV-2 Variants of Concern among Healthy Thai Populations.
Sudjaritruk T; Mueangmo O; Saheng J; Winichakoon P; Salee P; Wongjak W; Chaito T; Praparattanapan J; Nuket K; Solai N; Wipasa J; Chawansuntati K; Chaiwarith R
Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992147
[TBL] [Abstract][Full Text] [Related]
5. Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine.
Bookstein Peretz S; Regev N; Novick L; Nachshol M; Goffer E; Ben-David A; Asraf K; Doolman R; Levin EG; Regev Yochay G; Yinon Y
Ultrasound Obstet Gynecol; 2021 Sep; 58(3):450-456. PubMed ID: 34198360
[TBL] [Abstract][Full Text] [Related]
6. Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222.
Perkmann T; Perkmann-Nagele N; Mucher P; Radakovics A; Repl M; Koller T; Jordakieva G; Wagner OF; Binder CJ; Haslacher H
Int J Infect Dis; 2021 Sep; 110():309-313. PubMed ID: 34332084
[TBL] [Abstract][Full Text] [Related]
7. Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (Comirnaty
Held J; Esse J; Tascilar K; Steininger P; Schober K; Irrgang P; Alsalameh R; Tenbusch M; Seggewies C; Bogdan C
Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696171
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
Front Immunol; 2021; 12():690698. PubMed ID: 34276681
[TBL] [Abstract][Full Text] [Related]
10. Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis.
Bartels LE; Ammitzbøll C; Andersen JB; Vils SR; Mistegaard CE; Johannsen AD; Hermansen MF; Thomsen MK; Erikstrup C; Hauge EM; Troldborg A
Rheumatol Int; 2021 Nov; 41(11):1925-1931. PubMed ID: 34476603
[TBL] [Abstract][Full Text] [Related]
11. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity, safety and clinical outcomes of the SARS-CoV-2 BNT162b2 vaccine in adolescents with type 1 diabetes.
Emeksiz HC; Hepokur MN; Şahin SE; Şirvan BN; Çiçek B; Önder A; Yıldız M; Aksakal DK; Bideci A; Ovalı HF; İşman F
Front Pediatr; 2023; 11():1191706. PubMed ID: 37435175
[TBL] [Abstract][Full Text] [Related]
13. Association of AZD1222 and BNT162b2 COVID-19 Vaccination With Thromboembolic and Thrombocytopenic Events in Frontline Personnel : A Retrospective Cohort Study.
Hviid A; Hansen JV; Thiesson EM; Wohlfahrt J
Ann Intern Med; 2022 Apr; 175(4):541-546. PubMed ID: 35103482
[TBL] [Abstract][Full Text] [Related]
14. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.
Danese E; Montagnana M; Salvagno GL; Peserico D; Pighi L; De Nitto S; Henry BM; Porru S; Lippi G
Clin Chem Lab Med; 2021 Aug; 59(9):1585-1591. PubMed ID: 33838087
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis.
Bensouna I; Caudwell V; Kubab S; Acquaviva S; Pardon A; Vittoz N; Bozman DF; Hanafi L; Faucon AL; Housset P
Am J Kidney Dis; 2022 Feb; 79(2):185-192.e1. PubMed ID: 34508833
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of the novel 2019 coronavirus disease (COVID-19) vaccines among people with epilepsy (PwE): A cross-sectional study.
Massoud F; Ahmad SF; Hassan AM; Alexander KJ; Al-Hashel J; Arabi M
Seizure; 2021 Nov; 92():2-9. PubMed ID: 34391030
[TBL] [Abstract][Full Text] [Related]
18. Comparing the human milk antibody response after vaccination with four COVID-19 vaccines: A prospective, longitudinal cohort study in the Netherlands.
Juncker HG; Mulleners SJ; Ruhé EJM; Coenen ERM; Bakker S; van Doesburg M; Harinck JE; Rood RD; Bouhuijs JH; Oomen M; de Groot PCJM; Pajkrt PD; Korosi A; van Goudoever PJB; van Gils MJ; van Keulen BJ
EClinicalMedicine; 2022 May; 47():101393. PubMed ID: 35465077
[TBL] [Abstract][Full Text] [Related]
19. [Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers].
Rojkovich B; Németh D; Török E; Szabó B; Pintér Á; Juhász I; Weidl M; Lányi É; Pável-Szecskó J; Lázár I; Perduk A; Reiter J; Nagy G; Nagy E; Géher P
Orv Hetil; 2021 Sep; 162(39):1551-1557. PubMed ID: 34570721
[TBL] [Abstract][Full Text] [Related]
20. Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).
Korth J; Jahn M; Dorsch O; Anastasiou OE; Sorge-Hädicke B; Eisenberger U; Gäckler A; Dittmer U; Witzke O; Wilde B; Dolff S; Kribben A
Viruses; 2021 Apr; 13(5):. PubMed ID: 33923063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]